There are currently 1887 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210
Recruiting
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: UCLA Hematology-Oncology, Los Angeles, California
Conditions: Small Cell Lung Cancer
Register for Updates
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531
Recruiting
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/06/2025
Locations: University of Southern California Keck School of Medicine, Los Angeles, California
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
NCT06391918
Recruiting
Protocol GVO-1102 is a phase 1, open label, multi-center study in adult patients with locally advanced or metastatic solid tumors. This study includes two parts: dose escalation and dose expansion. In the dose escalation phase, GEN2 will be administered at increasing dose levels via intravenous infusion or intratumoral injection on Days 1, 3 and 8 every 4 weeks. Valganciclovir will start dosing on Day 12 and continue for 10 days (through Day 21). Once a recommended dose has been defined in appro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Southern California-Keck School of Medicine, Los Angeles, California +1 locations
Conditions: Solid Tumor, Adult
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, Los Angeles, California +1 locations
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503
Recruiting
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate or severe asthma. WIN378 blocks the action of a protein called TSLP which causes inflammation in the lung and may contribute to your asthma control and symptoms. The study will test how doses of WIN378 are handled by your body (pharmacokinetics) and assess the safety of the medicine and will assess markers of asthma inflammation in your breath and in your blood, lung function and asth... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: WB Contracted Clinical Research Site, Los Angeles, California
Conditions: Asthma (Diagnosis)
Register for Updates
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347
Recruiting
EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older. Study details include: * The study duration per participant (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Sensa Health- Site Number : 8400038, Los Angeles, California
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Register for Updates
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
NCT06687967
Recruiting
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Dermatology Research Associates - Los Angeles- Site Number : 8400004, Los Angeles, California
Conditions: Lichen Simplex Chronicus
Register for Updates
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
Recruiting
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Advanced Breast Cancer
Register for Updates
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619
Recruiting
The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks * To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose The... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/06/2025
Locations: Teva Investigational Site 12088, Los Angeles, California +1 locations
Conditions: Asthma
Register for Updates
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056
Recruiting
This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during res... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/06/2025
Locations: USC Keck, Los Angeles, California +1 locations
Conditions: Migraine
Register for Updates
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
NCT04903080
Recruiting
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. The HER2 CAR T cells used in this trial are made from the patient's own blood. A new gene, called the H... Read More
Gender:
ALL
Ages:
Between 1 year and 22 years
Trial Updated:
08/05/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Ependymoma
Register for Updates
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT06092892
Recruiting
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
08/05/2025
Locations: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California
Conditions: Breast Cancer, Axillary Nodal Disease, Female Breast Cancer, Axilla; Breast, Mastectomy; Lymphedema, Tumor, Breast
Register for Updates